文献速递其他结缔组织病

估算肾小球滤过率是欧洲硬皮病试验与研究组数据库中系统性硬化症患者死亡率的标志物

Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于EUSTAR数据库3650例系统性硬化症(SSc)患者,评估估算肾小球滤过率(eGFR)与临床疾病及死亡率的关联。结果显示eGFR<60 ml/min者5年总生存率显著低于eGFR≥60 ml/min者,多变量分析中eGFR与总生存独立相关,但在硬皮病肾危象(SRC)患者中eGFR>30与<30 ml/min者5年总生存无显著差异。

要点

  • SSc患者eGFR<60 ml/min与5年总生存率降低独立相关。
  • 男性、收缩期肺动脉压和eGFR是多变量分析中总生存的关联因素。
  • SRC患者中eGFR>30与<30 ml/min的5年总生存无显著差异。

核心结论

  • eGFR是SSc患者总生存的预测风险因素。
  • eGFR在SRC患者中不是死亡的风险因素。

研究设计与样本

  • 纳入EUSTAR数据库中基线访视和第二次随访访视时具备计算eGFR所需条目的SSc患者。
  • 对所有SSc患者选择eGFR切点60 ml/min,对硬皮病肾危象(SRC)患者选择30 ml/min。
  • 采用Cox回归和竞争风险分析评估eGFR作为死亡率预测因素的作用。

主要发现

  • 共纳入3650例SSc患者,血清肌酐中位数0.8 mg/dl(四分位距0.6-0.9),eGFR均值86.6 ± 23.7 ml/min。
  • 肺动脉高压患者eGFR显著更低。
  • eGFR<60 ml/min的SSc患者5年总生存率为0.763(95% CI: 0.700, 0.814),eGFR≥60 ml/min者为0.903(95% CI: 0.883, 0.919),P < 0.001。
  • 多变量分析中总生存与男性(P < 0.01)、收缩期肺动脉压(sPAP)(P < 0.001)和eGFR(P < 0.001)相关。
  • SSc所致死亡的累积发生率与sPAP升高(P < 0.001)和eGFR降低(P < 0.05)相关。

关键数值与推荐

  • 所有SSc患者eGFR切点为60 ml/min,SRC患者eGFR切点为30 ml/min。
  • 53例SRC患者中,eGFR>30 ml/min与eGFR<30 ml/min者5年总生存无显著差异。

临床怎么用

  • 在SSc患者中可监测eGFR以辅助评估总生存风险。
  • 对SRC患者,eGFR>30与<30 ml/min的5年总生存无显著差异,不宜仅据此判断死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study aim was to evaluate the estimated glomerular filtration rate (eGFR), its association with clinical disease and its predictive ability with respect to mortality in SSc patients from the European Scleroderma Trials and Research Group (EUSTAR) database. METHODS: SSc patients from the EUSTAR database who had items required for the calculation of eGFR at a baseline visit and a second follow-up visit available were included. A cut-off eGFR value of 60 ml/min was chosen for all SSc patients, and 30 ml/min for those with scleroderma renal crisis (SRC). Cox regression and competing risk analysis were performed to evaluate the use of eGFR as a predictive factor of mortality. RESULTS: A total of 3650 SSc patients were included in this study. The median serum level of creatinine and the mean of eGFR were 0.8 mg/dl (interquartile range = 0.6-0.9) and 86.6 ± 23.7 ml/min, respectively. The eGFR was significantly lower in patients with pulmonary hypertension. Overall survival (OS) was significantly reduced in SSc patients with eGFR < 60 ml/min compared with patients with eGFR ≥ 60 ml/min [OS at 5 years 0.763 (95% CI: 0.700, 0.814) vs 0.903 (95% CI: 0.883, 0.919; P < 0.001)]. In multivariable analysis, OS was associated with male gender (P < 0.01), systolic pulmonary arterial pressure (sPAP) (P < 0.001) and eGFR (P < 0.001). The cumulative incidence of deaths due to SSc was associated with increased sPAP (P < 0.001) and reduced eGFR (P < 0.05). The OS at 5 years of 53 SRC patients was not significantly different between SSc patients with eGFR > 30 ml/min and those with eGFR <30 ml/min. CONCLUSION: eGFR represents a predictive risk factor for overall survival in SSc. The eGFR, however, does not represent a risk factor for death in SRC.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gigante A, Hoffmann-Vold AM, Alunni Fegatelli D, et al. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. Rheumatology (Oxford). 2021. PMID: 33769468. doi:10.1093/rheumatology/keab302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。